Author:
Jeske Walter,Walenga ,Hoppensteadt ,Fareed Jawed
Subject
Health Policy,Pharmacology
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors;TH Open;2022-09-16
2. Bioequivalence of a biosimilar enoxaparin (
Cloti‐Xa™
) and its innovator (Clexane
®
): A
single‐dose
, randomized,
double‐blind
,
two‐period
,
two‐treatment
,
two‐sequence
, crossover, balanced study in healthy human subjects;Pharmacology Research & Perspectives;2022-06-28
3. Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial;Advances in Therapy;2021-03-09
4. Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version;Clinical and Applied Thrombosis/Hemostasis;2020-01-01
5. The impact of implemented regulations on biosimilars in Slovakia;HEALTH POLICY TECHN;2019